Abaxis, Inc. to Present at the Bank of America Merrill Lynch Animal Health Summit and the Raymond James 39th Annual Institutional Investors Conference
UNION CITY, Calif., Feb. 22, 2018 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care instruments and consumables for the medical and veterinary markets worldwide, announced today that Ross Taylor, Chief Financial Officer, will present at the following investor conferences:
Bank of America Merrill Lynch 2018 Animal Health Summit on Monday, February 26, 2018 at 3:15 p.m. ET. The conference will be held at the Bank of America Tower in New York City.
Raymond James 39th Annual Institutional Investors Conference on Monday, March 5, 2018 at 11:35 a.m. ET. The conference will be held at the JW Marriott Orlando Grande Lakes Hotel in Orlando, Florida.
About Abaxis
Abaxis, Inc. is a worldwide developer, manufacturer and marketer of portable blood analysis systems that are used in a broad range of medical specialties in human or veterinary patient care to provide clinicians with rapid blood constituent measurements. Our mission is to improve the efficiency of care delivery to and the quality of life of patients in the medical and veterinary markets. We provide leading edge technology and tools that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economical and profitable practices. For more information, visit http://www.abaxis.com.
Dental Care Acworth is thrilled to utilize this remarkable innovation and offer patients unbiased, objective and standardized dental care that they know they can trust. The AI solutions Pearl delivers can assist dental...
Tolland Hill Family Dental is thrilled to announce the addition of Dr. Conway Ma to its esteemed team of dental professionals. Tolland Hill Family Dental offers a wide range of services, catering to patients of all ages. From a child's first dental...
Amgen today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1...
Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for RAG-01, a...
Alera Health, a leader in population health management integrating behavioral healthcare, is proud to announce its recognition as one of the Great Employers to Work for in North Carolina by Best Companies Group.
The 2024 Great Employers to Work for...